AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
United Immunity raises ¥2.2B ($13.9M) in private equity and debt financing led by ITOCHU Corporation and others to advance UI-102 program for solid tumors and fibrotic diseases.
United Immunity, a Tokyo-based clinical-stage biotechnology company, raised ¥2.2B (approximately USD 13.9M) comprising ¥1.8B in private equity financing and ¥0.4B in debt financing. The funding was backed by a consortium of 13 investors including ITOCHU Corporation, Ono Venture Investment, and multiple life science investment partnerships. The company will use the proceeds to accelerate R&D of its lead program UI-102 and in vivo macrophage engineering programs targeting solid tumors and fibrotic diseases, while expanding R&D capabilities globally.
Company Information
Company
United Immunity
Location
Tokyo, Tokyo, Japan
About
United Immunity is a Tokyo-based clinical-stage biotechnology company developing a proprietary Myeloid Targeting Platform designed to selectively target and program macrophages and dendritic cells using pullulan-based nanoparticle technologies. The platform enables selective delivery of mRNA, siRNA, DNA, small molecules, and proteins to DC-SIGN-expressing myeloid cells for applications in cancer, fibrosis, autoimmune diseases, and infectious disease vaccines. The company is focused on accelerating R&D of its lead program UI-102 and in vivo macrophage engineering programs for treating solid tumors and fibrotic diseases.
Fundz sees it the moment United Immunity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TokyoBiotechnologyTherapeutics